Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational Study

NCT06868030 is registered in ClinicalTrials.gov with First Hospital of China Medical University as lead sponsor.

NCT NCT06868030
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06868030 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational Study
Lead sponsor
First Hospital of China Medical University
Phase
Observational
Overall status
Not yet recruiting
Start date
April 1, 2025
Completion date
December 31, 2026
Enrollment
120 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, mci-ad, early stage alzheimer's disease